U.S. flag An official website of the United States government
  1. Home
  2. Animal & Veterinary
  3. News & Events
  4. CVM Updates
  5. FDA Announces Animal Biotechnology Stakeholder Virtual Outreach Session
  1. CVM Updates

FDA Announces Animal Biotechnology Stakeholder Virtual Outreach Session

May 10, 2021

The FDA’s Center for Veterinary Medicine (CVM) is announcing an Animal Biotechnology Stakeholder Outreach Session that will be open to the public and will take place virtually on Wednesday, July 28 from 3:40 – 4:45 PM ET (2:40 - 3:45 PM CST) via Zoom. The session is open to all stakeholders at no cost, and will take place in conjunction with the Genome Writer’s Guild 2021 conference.  

At the session, CVM will collect feedback from stakeholders in order to enhance the predictability, transparency, and efficiency of the review process for intentional genomic alterations (IGAs) in animals. Specifically, the Veterinary Innovation Program (VIP) is available to most developers of IGAs in animals and is aimed at facilitating advancements in the development of innovative animal products by providing greater certainty in the regulatory process, encouraging development and research, and supporting an efficient and predictable pathway to approval. 

At the session, CVM will elaborate on its science- and risk-based approach for IGAs and will provide a brief overview of the agency’s risk analysis and review process. The session will conclude with breakout group listening/feedback sessions where stakeholders are encouraged to provide their input.  

Interested stakeholders can register for the session by filling out the form at the following link: https://fda.zoomgov.com/meeting/register/vJIsfuyqpj8sGkfbYZqSwVrP9I5F-yODE2c.  For stakeholders who are not able to attend the live Zoom session, you can email feedback to FDA-CVM-Animal-Biotechnology-Feedback@fda.hhs.gov

For more information: 

Animals with Intentional Genomic Alterations

FDA’s Veterinary Innovation Program 

Issued by FDA Center for Veterinary Medicine.
For questions, Contact CVM.

Back to Top